Pathogenesis and treatment of pruritus

Current Allergy and Asthma Reports

Volumn 10, Issue 4, 2010, Pages 236-242

  Greaves, Malcolm W ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Antipruritics; Neuropeptides; Neurophysiology; Pruritus

Indexed keywords

ANTIHISTAMINIC AGENT; APREPITANT; BUTORPHANOL; COLESTYRAMINE; DOXEPIN; HISTAMINE H1 RECEPTOR ANTAGONIST; NALMEFENE; NALOXONE; NALTREXONE; PSORALEN; RIFAMPICIN; URSODEOXYCHOLIC ACID; CYTOKINE; NEUROKININ 1 RECEPTOR; NEUROPEPTIDE;

CAUSAL ATTRIBUTION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOPATHOGENESIS; MEDIATOR RELEASE; NEUROLOGIC DISEASE; NEUROPHYSIOLOGY; NONHUMAN; PHOTOTHERAPY; PRURITUS; REVIEW; SYSTEMIC THERAPY; ADULT; CHILD; CHOLESTASIS; CHRONIC KIDNEY FAILURE; CLASSIFICATION; EPIDERMIS; KERATINOCYTE; MAST CELL; METABOLISM; PATHOPHYSIOLOGY;

ADULT; CHILD; CHOLESTASIS; CYTOKINES; EPIDERMIS; HUMANS; KERATINOCYTES; KIDNEY FAILURE, CHRONIC; MAST CELLS; NEUROPEPTIDES; PRURITUS; RECEPTORS, NEUROKININ-1;

EID: 77956393343     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-010-0117-z     Document Type: Review

References (55)

1. Yosipovitch G, Greaves MW, Schmelz M: Itch. Lancet 2003, 361:690-694.
2. Greaves MW, Khalifa N: Itch-more than skin deep. Int Arch Allergy Immunol 2004, 135:166-172.
3. Paus R, Schmelz M, Biro T, Steinhoff M: Frontiers in pruritus research: Scratching the brain for more effective therapy. J Clin Invest 2006, 116:1174-1186.
4. Twycross R, Greaves MW, Handwerker H, et al.: Itch: Scratching more than the surface. Q J Med 2003, 96:7-26.
5. Frey M: Zur Physiologie der Juckempfinding [in German]. Arch Neurol Physiol Neerl 1922, 7:142-145.
6. Inoue K, Koizumi S, Fuzuwara S, et al.: Functional vanilloid receptors in cultured human epidermal keratinocytes. Biochem Biophys Res Commun 2002, 291:124-129.
7. Bigliardi-Qi M, Lipp B, Sumanovski LT, et al.: Changes of epidermal mu-opiate receptor expression and nerve endings in atopic dermatitis. Dermatology 2005, 210:91-99.
8. Pincelli C: Neurotrophins in healthy and diseased skin [abstract]. J Invest Dermatol 2009, 129:S102.
9. Dunford PJ, Williams KN, Desai PJ, et al.: Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 2007, 119:176-183. Discovery of the H4 receptor and its potential role in itching offers the prospect of novel therapeutic approaches to treatment of itch.
10. McKemy DD, Neuhasser WM, Julius D: Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 2002, 416:52-58.
11. Darsow U, Drzezga A, Frisch M, et al.: Processing of histamineinduced itch in the human cerebral cortex: A correlation analysis with dermal reactions. J Invest Dermatol 2000, 115:1029-1033.
12. Schmelz M: A neural pathway for itch. Nat Neurosci 2001, 4:9-10.
13. Andrew D, Craig AD: Spinothalamic lamina 1 neurons selectively sensitive to histamine: A central neural pathway for itch. Nat Neurosci 2001, 4:72-77.
14. Mochizuki H: Imaging of central itch modulation in the human brain using positron emission tomography. Pain 2003, 105:339-346.
15. Wall PD, McMahon SB: Microneuronography and its relation to perceived sensation. A critical review. Pain 1985, 21:209-229.
16. Bell JK, McQueen DS, Rees JL: Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in Balb C mice. Br J Pharmacol 2004, 142:374-380.
17. Vergnolle N, Ferazzini M, D'Andrea MR, et al.: Proteinaseactivated receptors: Novel signals for peripheral nerves. Trends Neurosci 2003, 26:496-500.
18. Ballantyne JC, Loach AB, Carr DB: Itching after epidural and spinal opiates. Pain 1988, 33:19-60.
19. Bergasa NV, Talbot TL, Alling DW, et al.: A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992, 102:544-559.
20. Wahlgren CF, Tengvall Linder M, Hagermark O, Scheynius A: Itch and inflammation induced by intradermally injected interleukin-2 in atopic dermatitis patients and healthy subjects. Arch Dermatol Res 1995, 287:572-580.
21. Zhang Q, Putheu P, Zhou Q, et al.: Structure and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev 2008, 19:347-356. The recent discovery of interleukin-31 and its receptor, which is overexpressed in the itchy skin of atopic dermatitis, promises a new therapeutic approach to antipruritic therapy in this disorders.
22. Sonkoly E, Muller A, Lauerma AI, et al.: IL-31: A new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006, 117:411-417.
23. Dillon SR, Sprecher C, Hammond A, et al.: Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004, 5:752-760.
24. Tanaka A, Arita K, Lai-Chong JE, et al.: New insight into mechanisms of pruritus from molecular studies on familial primary localised cutaneous amyloidosis. Br J Dermatol 2009, 161:1217-1224.
25. Johansson O, Liang Y, Emtestam L: Increased nerve growth factor and tyrosine kinase- like immunoreactivities in prurigo nodularis skin: An exploration of the cause of neurohyperplasia. Arch Derm Res 2002, 293:614-619.
26. Tanaka A, Matsuda H: Expression of nerve growth factor in itchy skins of atopic NC/NgaTnd mice. J Vet Med Sci 2005, 67:915-919.
27. Chang S-E, Han S-S, Jung H-J, Choi J-H: Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol 2007, 156:1272-1277.
28. Toyoda M, Nakamura M, Makino T, et al.: Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol 2002, 147:71-79.
29. Peer G, Kivity S, Agami O, et al.: Randomised cross-over trial of naltrexone in uremic pruritus. Lancet 1996, 348:1552-1554.
30. Pauli-Magnus C, Mikus G, Alscher DM, et al.: Naltrexone does not relieve uremic pruritus. Results of a randomised double blind, placebo controlled cross over study. J Am Soc Nephrol 2000, 11:514-519.
31. Tan KL, Haberman HF, Coldman AJ: Identifying effective treatments for uremic pruritus. J Am Acad Dermatol 1991, 24:811-818.
32. Bergasa, NV, Thomas DA, Vergalla J, et al.: Plasma from patients with pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci 1993, 53:1253-1257.
33. Goulis, J, Leandro G, Burroughs AK: Randomised controlled trials of ursodeoxycholic acid therapy for primary biliary cirrhosis: A meta analysis. Lancet 1999, 355:657-658.
34. Ghent CN, Carruthers SG: Treatment of pruritus in primary biliary cirrhosis with rifampicin: Results of a double blind crossover randomised trial. Gastroenterology 1988, 94:488-493.
35. Bachs L, Pares A, Elena M, et al.: Comparison of rifampicin with phenobarbitone for the treatment of pruritus in biliary cirrhosis. Lancet 1989, 638:574-576.
36. Bergasa N, Alling DW, Talbot TL, et al.: Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study. J Am Acad Dermatol 1999, 41:431-444.
37. Bergasa N, Alling DW, Talbot TL, et al.: Naloxone ameliorates the pruritus of cholestasis: Results of a double blind, randomized, placebo-controlled trial. Ann Intern Med 1995, 123:161-167.
38. Neilly JB, Martin A, Simpson N, MacCuish AC: Pruritus in diabetes mellitus: Investigation of prevalence and correlation with diabetes control. Diabetes Care 1986, 9:273-275.
39. Steinman HK, Black AK, Lotti TM, et al.: Polycythaemia vera and water-induced pruritus. Blood histamine levels and cutaneous fibrinolytic activity before and after water challenge. Br J Dermatol 1987, 116:329-333.
40. du Peloux Menagé H, Greaves MW: Aquagenic pruritus. Semin Dermatol 1995, 14:313-316.
41. Ward JR, Bernhard JD: Willan's itch and other causes of pruritus in the elderly. Int J Dermatol 2005, 44:267-273.
42. Simons FER: Advances in H1 antihistamines. N Engl J Med 2004, 351:2203-2217.
43. Klein PA, Clark RAE: An evidence-based review of the efficacy of antihistamines in relieving the pruritus of atopic dermatitis. Arch Dermatol 1999, 135:484-488.
44. Figueiredo A, Ribeiro A, Goncalo M, et al.: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol 1990, 4:147-158.
45. Metze D, Reimann S, Beissert S, Luger T: Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol 1999, 41:553-559.
46. Dawn AG, Yosipovitch G: Butorphenol for treatment of intractable pruritus. J Am Acad Dermatol 2006, 54:527-531.
47. Duval A, Dubetret L: Aprepitant as an antipruritic agent? N Engl J Med 2009, 361:1415-1416. This neurokinin receptor antagonist has been shown to ameliorate one of the most intractable generalized itches-the pruritus of Sézary syndrome.
48. De Esch IJP, Thurmond RL, Jongelan A, Leurs R: The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci 2005, 26:462-469.
49. Vogelsang M, Heyer G, Hornstein OP: Acetyl choline induces different sensations in atopic and non-atopic subjects. Acta Derm Venereol 1995, 75:434-436.
50. Andoh T, Saito A, Kuraishi Y: Leukotriene B4 mediates sphingosylphosphorylcholine-induced itch-associated responses in mouse skin. J Invest Dermatol 2009, 129:2854-2860.
51. Rivard J, Lim HW: Ultraviolet phototherapy for pruritus. Dermatol Ther 2005, 18:344-354.
52. Duque MI, Yosipovitch G, Fleischer AB, et al.: Lack of efficacy of tacrolimus ointment 0.1% for the treatment of hemodialysisrelated pruritus: A randomized, double-blind, vehicle-controlled study. J Am Acad Dermatol 2005, 52:519-521.
53. Ashmore SD, Jones CH, Newstead CD, et al.: Odansetron therapy for uremic pruritus in hemodialysis patients. Am J Kidney Dis 2000, 35:827-831.
54. Gunal AI, Ozalp G, Yoldas TK, et al.: Gabapentin therapy for pruritus in haemodialysis patients: A randomized, placebocontrolled, double-blind trial. Nephrol Dial Transplant 2004, 19:3137-3139.
55. Wikstrom B, Gellert R, Ladefoged SD, et al.: Kappa-opioid system in uremic pruritus: Multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005, 16:3742-3747.